Receipt of novel hormonal therapy for advanced prostate cancer varies with race

For Medicare beneficiaries with advanced prostate cancer (PCa), receipt of novel hormonal therapy (NHT) agents varies with race, according to a study published online Dec. 1 in JAMA Network Open.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.